Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,713JPY
21 Sep 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
¥4,713
Open
¥4,715
Day's High
¥4,734
Day's Low
¥4,683
Volume
5,761,400
Avg. Vol
4,291,976
52-wk High
¥6,693
52-wk Low
¥4,203

Latest Key Developments (Source: Significant Developments)

Seattle Genetics Announces Adcetris Approval In Japan
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES ADCETRIS® (BRENTUXIMAB VEDOTIN) APPROVAL IN JAPAN FOR FRONTLINE HODGKIN LYMPHOMA.SEATTLE GENETICS INC - JAPANESE APPROVAL TRIGGERS MILESTONE PAYMENT TO CO OF $10 MILLION.  Full Article

EMA Recommendations For August 2018
Friday, 21 Sep 2018 

Sept 21 (Reuters) - European Medicines Agency::EUROPEAN MEDICINES AGENCY RECOMMENDATIONS FOR AUGUST 2018.RECOMMENDS APPROVAL OF ELI LILLY’S GALCANEZUMAB.RECOMMENDS APPROVAL OF TAKEDA’S BRIGATINIB.RECOMMENDS APPROVAL OF SPARK THERAPEUTICS’ VORETIGENE NEPARVOVEC LUXTURNA.RECOMMENDS APPROVAL OF BAYER’S DAMOCTOCOG ALFA PEGOL .  Full Article

Molecular Templates Announces Deal With Takeda
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Molecular Templates Inc ::MOLECULAR TEMPLATES ANNOUNCES AGREEMENT WITH TAKEDA FOR THE JOINT DEVELOPMENT OF A PROTEIN-BASED ONCOLOGY THERAPY.MOLECULAR TEMPLATES INC - TAKEDA WILL MAKE AN UPFRONT PAYMENT OF $30 MILLION.MOLECULAR TEMPLATES - CO ELIGIBLE TO RECEIVE DEVELOPMENT, OTHER MILESTONE PAYMENTS OF UPTO $632.5 MILLION IF CO EXERCISES ITS CO-DEVELOPMENT OPTION.MOLECULAR TEMPLATES - ELIGIBLE TO RECEIVE DEVELOPMENT, OTHER MILESTONE PAYMENTS OF $337.5 MILLION IF IT DOESN'T EXERCISE OR OPTS OUT OF CO-DEVELOPMENT OPTION.MOLECULAR TEMPLATES INC - TAKEDA HAS ALSO AGREED TO PAY ROYALTIES ON SALES OF COMMERCIAL PRODUCT DEVELOPED THROUGH COLLABORATION.MOLECULAR TEMPLATES - AGREEMENT WITH TAKEDA PHARMACEUTICAL COMPANY LIMITED FOR JOINT DEVELOPMENT OF CD38-TARGETED ENGINEERED TOXIN BODIES.  Full Article

Takeda Is Said To Weigh Sale Of Shire Eye Care Drug To Cut Debt - Bloomberg
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - :TAKEDA IS SAID TO WEIGH SALE OF SHIRE EYE CARE DRUG TO CUT DEBT - BLOOMBERG, CITING SOURCES.  Full Article

Takeda Pharmaceutical completes acquisition of TiGenix following expiration of squeeze-out period
Tuesday, 31 Jul 2018 

July 31(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it completes its acquisition of TiGenix following expiration of the squeeze-out period.Takeda has acquired all outstanding ordinary shares(including ordinary shares represented by American Depositary Shares) and warrants of TiGenix following the expiration of the squeeze-out period.  Full Article

Takeda Q1 Earnings Per Share JPY 100
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA REPORTS FIRST QUARTER FY2018 RESULTS.Q1 EARNINGS PER SHARE JPY 100.00.  Full Article

Takeda Pharmaceutical Announces Statement Regarding US FTC Clearance
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Takeda Pharmaceutical Company Ltd <4502.T>::STATEMENT REGARDING US FTC CLEARANCE.TAKEDA RECEIVES CLEARANCE FROM UNITED STATES FEDERAL TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE PLC.  Full Article

Takeda And Tigenix Announce Results Of Second Acceptance Period For The Voluntary And Conditional Public Takeover Bid
Friday, 6 Jul 2018 

July 6 (Reuters) - Tigenix Nv ::TAKEDA AND TIGENIX ANNOUNCE RESULTS OF SECOND ACCEPTANCE PERIOD FOR THE VOLUNTARY AND CONDITIONAL PUBLIC TAKEOVER BID IN RESPECT OF TIGENIX AND COMMENCEMENT OF SIMPLIFIED SQUEEZE-OUT AND INTENTION TO DELIST THE ADSS FROM NASDAQ....FOLLOWING SETTLEMENT OF SECURITIES, TAKEDA WILL OWN 96.08% OF OUTSTANDING ORDINARY SHARES.THE SQUEEZE-OUT PERIOD WILL COMMENCE TODAY, JULY 6, 2018, AND WILL EXPIRE ON JULY 26, 2018.  Full Article

Takeda Pharmaceutical and ASKA Pharmaceutical enter into licensing agreement for relugolix in women's health indications
Thursday, 31 May 2018 

May 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it and ASKA Pharmaceutical Co Ltd <<<4514.T>>> announced today that they entered inter a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned relugolix.Based on this agreement, Takeda will receive upfront payment for granting the exclusive commercialization right for uterine fibroids and the exclusive development and commercialization rights for endometriosis in Japan as well as holding the right to receive royalties on sales.  Full Article

Proposed acquisition of Shire by Takeda Pharmaceutical
Tuesday, 8 May 2018 

May 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Takeda Pharmaceutical Company Limited and Shire plc today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.Under the terms of the acquisition, each Shire shareholder will be entitled to receive $30.33 in cash for each Shire share and either 0.839 new Takeda shares or 1.678 Takeda ADSs.Shire shareholders will own about half of the combined group after the deal .  Full Article

Takeda lung cancer drug gets European panel nod

Sept 21 Takeda Pharmaceutical Co's lung cancer drug received the recommendation of a European Union panel on Friday, more than a year after it won regulatory approval to be sold in the United States.